Over the course of the past year, iBio (NYSEAMERICAN:IBIO) emerged as one of the more interesting stocks in the market and it got considerable attention at the start of the COVID 19 pandemic.
The company is the owner of a proprietary system that helps in the producing of proteins from plants and when the pandemic had just started, iBio had also come up with a vaccine candidate of its own named IBIO 201. That had sent the stock soaring but IBIO 201 was not actually selected for Operation Warp Speed.
On top of that, the company also became embroiled in a lawsuit that challenged its intellectual property in relation its FastPharming technology. While it is true that the company’s bid for a COVID 19 vaccine did not end well, there are still positives to be considered. The most important thing to remember is that the company’s FastPharming technology could still make it big and hence, it might be a good move for investors with risk tolerance to consider the iBio stock.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.